PRAC adopted updates to the SmPC for Talzenna to support an extension of indication in combination with enzalutamide for adults with homologous recombination repair (HRR) gene-mutated metastatic hormone-sensitive prostate cancer.

Talzenna (talazoparib) - Pfizer

Sep 1, 2026